They aim to liberate patients from the burden of serious chronic disease
They have the courage to revolutionize medicine and create a first-in-class therapeutic category to liberate patients from chronic disease.
Their name is derived from sigilo – a Spanish word meaning stealth. Stealth is a key attribute of their Shielded Living Therapeutics™ platform, which they are using to harness the power of therapeutic cells without inducing an immune response.
Serious chronic diseases today are often treated with chronic therapies. For patients with diseases such as hemophilia, type 1 diabetes or lysosomal storage disorders, this amounts to less than ideal clinical outcomes combined with frequent injections and infusions — sometimes multiple times daily — and constant, lifelong vigilance to manage their disease.
There is a better way. At Sigilon they are pioneering Shielded Living Therapeutics™ as a novel treatment for a wide range of chronic diseases. Shielded Living Therapeutics™ can recapitulate, restore and replace many natural biological functions.See more